FDA批准Pfizer的Hympavzi, 一周一次的血友病治疗会增加血凝结。 FDA approves Pfizer's Hympavzi, a once-weekly hemophilia treatment enhancing blood clotting.

美国食品药品监督管理局批准了瑞公司的新型治疗血友病A和B的新药Hympavzi, The FDA has approved Pfizer's Hympavzi, a new treatment for hemophilia A and B, marking a significant advancement in the market. 与传统疗法不同,Hympavzi减少了天然抗凝胶剂的活动,增加了血凝胶。 Unlike traditional therapies, Hympavzi reduces the activity of a natural anticoagulant, enhancing blood clotting. 提供每周一次皮下注射, 解决了更容易治疗的需求. It offers a once-weekly subcutaneous administration, addressing a need for easier treatment. 批准是血友病市场上向个性化药物转变的一部分,此外还有Hemlibra和基因治疗等其他疗法。 The approval is part of a shift towards personalized medicine in the hemophilia market, alongside other therapies like Hemlibra and gene treatments.